The Week in Review: April 28 – May 11, 2018

Friday, May 11, 2018 News Recap: HBV: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B. The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost prepar...

Biologic Psoriasis Therapies Pose Limited Risk for Hepatitis B Reactivation

A recent systematic review of the literature has confirmed that biologic therapies can reactivate hepatitis B virus (HBV) in patients with plaque psoriasis.  Although the study found that any prior HBV exposure was associated with the risk for viral reactivation, patients with chronic HBV were far more likely to experience reactivation than those with evidence of HBV exposure but without hepatitis. Antiviral prophylaxis greatly reduced the risk for viral r